|
2019 Conference Publication Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study)Pelletier, Daniel, Arnold, Douglas L., Boyko, Alexey N., Comi, Giancarlo, Hartung, Hans-Peter, Havrdova, Eva Kubala, Inshasi, Jihad Said, McCombe, Pamela, Nakamura, Kunio, Oreja-Guevara, Celia, Pozzilli, Carlo, Selmaj, Krzysztof W., Scott, Thomas F., Chung, Luke, Daizadeh, Nadia, Afsar, Salman and Van Wijmeersch, Bart (2019). Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study). 71st Annual Meeting of the American-Academy-of-Neurology (AAN), Philadelphia Pa, May 04-10, 2019. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2019 Conference Publication Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study)Pelletier, Daniel, Arnold, Douglas L., Boyko, Alexey N., Comi, Giancarlo, Hartung, Hans-Peter, Havrdova, Eva Kubala, Inshasi, Jihad Said, McCombe, Pamela, Nakamura, Kunio, Oreja-Guevara, Celia, Pozzilli, Carlo, Selmaj, Krzysztof W., Scott, Thomas F., Chung, Luke, Daizadeh, Nadia, Afsar, Salman and Van Wijmeersch, Bart (2019). Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study). AAN 71st Annual Meeting, Philadelphia, PA United States, 4-10 May 2019. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.92.15_supplement.p3.2-037 |
|
2019 Conference Publication Clinical determinants and therapeutic modifiers of relapse and disability outcomes in neuromyelitis optica spectrum disorderKunchok, Amy, Malpas, Charles, Nytrova, Petra, Havrdova, Eva, Alroughani, Raed, Terzi, Murat, Yamout, Bassem, Hor, Jyh Yung, Karabudak, Rana, Boz, Cavit, Ozakbas, Serkan, Olascoaga Urtaza, Francisco Javier, Simo, Magdolna, Granella, Franco, Patti, Francesco, McCombe, Pamela, Csepany, Tunde, Singhal, Bhim, Bergamaschi, Roberto, Fragoso, Yara, Al-Harbi, Talal, Turkoglu, Recai, Lechner-Scott, Jeannette, Laureys, Guy, Oreja-Guevara, Celia, Pucci, Eugenio, Sola, Patrizia, Ferraro, Diana, Altintas, Ayse ... Kalincik, Tomas (2019). Clinical determinants and therapeutic modifiers of relapse and disability outcomes in neuromyelitis optica spectrum disorder. 71st Annual Meeting of the American-Academy-of-Neurology (AAN), Philadelphia, PA, United States, 4-10 May 2019. Philadelphia, PA, United States: Wolters Kluwer Health. |
|
2019 Conference Publication Investigating the Effect of Teriflunomide on Brain Volume Loss in the Phase 3 TOPIC StudySprenger, Till, Lebrun-Frenay, Christine, Vermersch, Patrick, Park, Min Su, Chinchilla, Dennis, McCombe, Pamela, Lincoln, John, Kappos, Ludwig, Bergsland, Niels, Dwyer, Michael, Cavalier, Steven, Roesch, Nora, Somera-Molina, Kathleen, Poole, Elizabeth and Zivadinov, Robert (2019). Investigating the Effect of Teriflunomide on Brain Volume Loss in the Phase 3 TOPIC Study. 71st Annual Meeting of the American-Academy-of-Neurology (AAN), Philadelphia Pa, May 04-10, 2019. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2019 Journal Article Cumulative influence of parity-related genomic changes in multiple sclerosisMehta, Divya, Wani, Shivangi, Wallace, Leanne, Henders, Anjali K., Wray, Naomi R. and McCombe, Pamela A. (2019). Cumulative influence of parity-related genomic changes in multiple sclerosis. Journal of Neuroimmunology, 328, 38-49. doi: 10.1016/j.jneuroim.2018.12.004 |
|
2019 Journal Article Tract integrity in amyotrophic lateral sclerosis: 6–month evaluation using MR diffusion tensor imagingAlruwaili, Ashwag R., Pannek, Kerstin, Henderson, Robert D., Gray, Marcus, Kurniawan, Nyoman D. and McCombe, Pamela A. (2019). Tract integrity in amyotrophic lateral sclerosis: 6–month evaluation using MR diffusion tensor imaging. BMC Medical Imaging, 19 (1) 19, 19. doi: 10.1186/s12880-019-0319-3 |
|
2019 Journal Article Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: a contemporary cohort studyNguyen, Ai-Lan, Havrdova, Eva Kubala, Horakova, Dana, Izquierdo, Guillermo, Kalincik, Tomas, van der Walt, Anneke, Terzi, Murat, Alroughani, Raed, Duquette, Pierre, Girard, Marc, Prat, Alexandre, Boz, Cavit, Sola, Patrizia, Ferraro, Diana, Lugaresi, Alessandra, Lechner-Scott, Jeannette, Barnett, Michael, Grand'Maison, Francois, Grammond, Pierre, Ramo-Tello, Cristina, Turkoglu, Recai, McCombe, Pamela, Pucci, Eugenio, Trojano, Maria, Granella, Franco, Spitaleri, Daniele, Van Pesch, Vincent, Soysal, Aysun, Oreja-Guevara, Celia ... Jokubaitis, Vilija (2019). Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: a contemporary cohort study. Multiple Sclerosis and Related Disorders, 28, 235-243. doi: 10.1016/j.msard.2019.01.003 |
|
2019 Journal Article Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosisBrown, J. William L., Coles, Alasdair, Horakova, Dana, Havrdova, Eva, Izquierdo, Guillermo, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Trojano, Maria, Lugaresi, Alessandra, Bergamaschi, Roberto, Grammond, Pierre, Alroughani, Raed, Hupperts, Raymond, McCombe, Pamela, Van Pesch, Vincent, Sola, Patrizia, Ferraro, Diana, Grand'Maison, Francois, Terzi, Murat, Lechner-Scott, Jeannette, Flechter, Schlomo, Slee, Mark, Shaygannejad, Vahid, Pucci, Eugenio, Granella, Franco, Jokubaitis, Vilija, Willis, Mark, Rice, Claire ... Robertson, Neil (2019). Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA - Journal of the American Medical Association, 321 (2), 175-187. doi: 10.1001/jama.2018.20588 |
|
2019 Conference Publication Pregnancy Outcomes in Patients with MS Treated with Teriflunomide: Clinical Study and Postmarketing DataMcCombe, P., Vukusic, S., Coyle, P. K., Jurgensen, S., Truffinet, P., Benamor, M., Poole, E., Chavin, J. and Chambers, C. (2019). Pregnancy Outcomes in Patients with MS Treated with Teriflunomide: Clinical Study and Postmarketing Data. Congress of the Pan Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS), Sydney, NSW Australia, 2018. London, United Kingdom: Sage. |
|
2019 Conference Publication Cladribine: a multicentre long-term efficacy biomarker australian study (CLOBAS)Lechner-Scott, Jeannette, Maltby, Vicky, Lyndon, Amanda, Monif, Mastura, Kilpatrick, Trevor, Butzkueven, Helmut, Taylor, Bruce, McCombe, Pamela, Hodgkinson, Suzanne, Fabis-Pedrini, Marzena, Kermode, Allan, Barnett, Michael and Kalincik, Tomas (2019). Cladribine: a multicentre long-term efficacy biomarker australian study (CLOBAS). Annual Scientific Meeting of the Australian and New Zealand Association of Neurologists (ANZAN), Sydney, Australia, May 21-24, 2019. London, United Kingdom: B M J Group. doi: 10.1136/jnnp-2019-anzan.119 |
|
2019 Conference Publication Alemtuzumab maintains efficacy on clinical and MRI disease activity outcomes, including slowing of brain volume loss, over 9 years in RRMS patients: CARE-MS I follow-up (TOPAZ study)Montalban, X., Arnold, D. L., Boyko, A. N., Comi, G., Hartung, H.-P., Havrdova, E. K., Inshasi, J. S., McCombe, P., Nakamura, K., Oreja-Guevara, C., Pelletier, D., Pozzilli, C., Scott, T. F., Vieira Alves Leon, S., Chung, L., Daizadeh, N., Afsar, S. and Selmaj, K. W. (2019). Alemtuzumab maintains efficacy on clinical and MRI disease activity outcomes, including slowing of brain volume loss, over 9 years in RRMS patients: CARE-MS I follow-up (TOPAZ study). 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm Sweden, 11-13 September 2019. London, United Kingdom: Sage Publications. |
|
2019 Conference Publication Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study)McCombe, P., Comi, G., Arnold, D. L., Boyko, A. N., Hartung, H-P., Havrdova, E. K., Inshasi, J. S., Nakamura, K., Oreja-Guevara, C., Pelletier, D., Pozzilli, C., Selmaj, K. W., Scott, T. F., Chung, L., Daizadeh, N., Afsar, S. and Van Wijmeersch, B. (2019). Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study). Congress of the Pan Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS), Sydney, NSW Australia, 2018. London, United Kingdom: Sage. |
|
2019 Journal Article Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosisKalincik, Tomas, Kubala Havrdova, Eva, Horakova, Dana, Izquierdo, Guillermo, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grammond, Pierre, Onofrj, Marco, Lugaresi, Alessandra, Ozakbas, Serkan, Kappos, Ludwig, Kuhle, Jens, Terzi, Murat, Lechner-Scott, Jeannette, Boz, Cavit, Grand'Maison, Francois, Prevost, Julie, Sola, Patrizia, Ferraro, Diana, Granella, Franco, Trojano, Maria, Bergamaschi, Roberto, Pucci, Eugenio, Turkoglu, Recai, McCombe, Pamela A, Pesch, Vincent Van, Van Wijmeersch, Bart, Solaro, Claudio ... Butzkueven, Helmut (2019). Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 90 (4), 458-468. doi: 10.1136/jnnp-2018-319831 |
|
2019 Conference Publication Postpartum relapse after first on-study pregnancy in RRMS patients treated with alemtuzumab in the phase 2 and 3 clinical development program over 8 yearsCelius, E. G., Achiron, A., Compston, D. A. S., Derwenskus, J., Devonshire, V., Hellwig, K., Hutton, G. J., McCombe, P., Moore, M., Oh, J., Simm, R. F., Sousa, L., Vincent, S. G., Chung, L., Daizadeh, N., Mitchell, C. and Rog, D. (2019). Postpartum relapse after first on-study pregnancy in RRMS patients treated with alemtuzumab in the phase 2 and 3 clinical development program over 8 years. 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm Sweden, 11-13 September 2019. London, United Kingdom: Sage Publications. |
|
2018 Journal Article The short and long-term effects of pregnancy on multiple sclerosis and experimental autoimmune encephalomyelitisMcCombe, Pamela A. (2018). The short and long-term effects of pregnancy on multiple sclerosis and experimental autoimmune encephalomyelitis. Journal of Clinical Medicine, 7 (12) 494, 494. doi: 10.3390/jcm7120494 |
|
2018 Journal Article Association of inflammation and disability accrual in patients with progressive-onset multiple sclerosisHughes, Jordana, Jokubaitis, Vilija, Lugaresi, Alessandra, Hupperts, Raymond, Izquierdo, Guillermo, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grand'maison, Francois, Grammond, Pierre, Sola, Patrizia, Ferraro, DIana, Ramo-Tello, Cristina, Trojano, Maria, Slee, Mark, Shaygannejad, Vahid, Boz, Cavit, Lechner-Scott, Jeanette, Van Pesch, Vincent, Pucci, Eugenio, Solaro, Claudio, Verheul, Freek, Terzi, Murat, Granella, Franco, Spitaleri, Daniele, Alroughani, Raed, Jun, Jae-Kwan, Fambiatos, Adam, Van Der Walt, Anneke ... Hinson, Eloise (2018). Association of inflammation and disability accrual in patients with progressive-onset multiple sclerosis. JAMA Neurology, 75 (11), 1407-1415. doi: 10.1001/jamaneurol.2018.2109 |
|
2018 Conference Publication Clinical and therapeutic predictors of relapse and disability outcomes in neuromyelitis optica spectrum disorderKunchok, A., Malpas, C., Horakova, D., Havrdova, E., Alroughani, R., Terzi, M., Yamout, B., Karabudak, R., Boz, C., Ozakbas, S., Olascoagam, J., Simon, M., Granellau, F., McCombe, P., Csepanym, T., Bergamaschi, R., Fragoso, Y., Al-Harbin, T., Turkoglu, R., Lechner-Scott, J., Laureys, G., Pucci, E., Sola, P., Ferraro, D., Altintas, A., Grand'Maison, F., Izquierdo, G., Eichau, S., Lugaresi, A. ... Kalincik, T. (2018). Clinical and therapeutic predictors of relapse and disability outcomes in neuromyelitis optica spectrum disorder. 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin Germany, Oct 10-12, 2018. LONDON: SAGE PUBLICATIONS LTD. |
|
2018 Conference Publication Disability outcomes in patients with early cerebellar symptoms in multiple sclerosisLe, M. V. H., Malpas, C., Sharmin, S., Horakova, D., Havrdova, E. K., Trojano, M., Izquierdo, G., Eichau, S., Ozakbas, S., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Alroughani, R., Bergamaschi, R., Sola, P., Grammond, P., Grand'Maison, F., Terzi, M., Boz, C., Hupperts, R., Butzkueven, H., Van der Walt, A., Pucci, E., Granella, F., Van Pesch, V., Soysa, A., Yamout, B., Lechner-Scott, J. ... Kalincik, T. (2018). Disability outcomes in patients with early cerebellar symptoms in multiple sclerosis. 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin Germany, Oct 10-12, 2018. LONDON: SAGE PUBLICATIONS LTD. |
|
2018 Conference Publication Early clinical predictors of severe MSMalpas, C., Sharmin, S., Horakova, D., Havrdova, E. K., Trojano, M., Izquierdo, G., Bergamaschi, R., Sola, P., Ferraro, D., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Grammond, P., Grand'Maison, F., Ozakbas, S., Van Pesch, V., Granella, F., Hupperts, R., Pucci, E., Boz, C., Iuliano, G., Sidhom, Y., Gouider, R., Spitaleri, D., Butzkueven, H., Soysal, A., Petersen, T., Verheul, F. ... Kalincik, T. (2018). Early clinical predictors of severe MS. 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin Germany, Oct 10-12, 2018. LONDON: SAGE PUBLICATIONS LTD. |
|
2018 Conference Publication Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registrySpelman, T., Harvrdova, E. K., Horakova, D., Izquierdo, G., Kalincik, T., Lugaresi, A., Onofrj, M., Duquette, P., Girard, M., Prat, A., Grammond, P., Grand'Maison, F., Granella, F., Lechner-Scott, J., Sola, P., Ferrero, D., Sa, M. J., Terzi, M., Ozakbas, S., Van Pesch, V., Van Wijmeersch, B., Boz, C., Karabudak, R., Cartechini, E., McCombe, P. and Butzkueven, H. (2018). Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry. 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin Germany, Oct 10-12, 2018. LONDON: SAGE PUBLICATIONS LTD. |
